Trust Signals
Written by the FormBlends Medical Team. All claims are graded by evidence type. No human clinical trial data exists for FOXO4-DRI dosing; this page separates the single published mouse study from extrapolated human protocols and clearly marks the difference. No doses are recommended here for human use. Updated 2026-05-29.
Key Takeaways
- The only published efficacy data comes from Baar et al. (2017, Cell), which used 5 mg/kg intraperitoneally in mice, three times per week. No equivalent human trial exists.
- FOXO4-DRI is a retro-inverso peptide: its D-amino acid backbone resists proteolytic degradation compared to an all-L equivalent, which is why injectable rather than oral use is still required but why solution stability is somewhat better than most research peptides.
- Human protocols circulating in self-experimentation communities use 1 to 2 mg/kg subcutaneously, but these doses have no clinical trial support and the human safety profile is entirely unknown.
- At 5 mg/kg (the mouse study dose), an 80 kg person would require 400 mg per injection, a cost- and safety-prohibitive quantity never tested in humans.
- Peptide purity from unregulated suppliers varies dramatically. A certificate of analysis (COA) showing HPLC purity above 98% and mass spectrometry confirmation of molecular weight is the minimum sourcing standard.
What Is the FOXO4-DRI Dosage Used in Research?
The only peer-reviewed animal efficacy study for FOXO4-DRI dosage is Baar et al. (2017) in Cell. That study injected mice at 5 mg/kg intraperitoneally three times per week and observed selective apoptosis of p21-positive senescent cells, along with improvements in fitness, hair density, and kidney function in fast-aging XFE progeroid mice. No human clinical trial has tested any FOXO4-DRI dose. All human dosing figures are researcher extrapolations or self-experimentation reports, not validated clinical data.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- How FOXO4-DRI Works and Why the Dose Matters
- Evidence Ledger: What the Data Actually Supports
- FOXO4-DRI Dosage Chart by Body Weight
- Injection Frequency and Protocol Structures
- Reconstitution and Operational Label Literacy
- What Most Dosage Pages Get Wrong
- Storage and Stability: The Chemistry Behind the Rules
- Honest Head-to-Head: FOXO4-DRI vs. Other Senolytics
- Failure Modes and Sourcing Reality
- FAQ
- Sources
How FOXO4-DRI Works and Why the Dose Matters
FOXO4-DRI is a 18-amino-acid retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 inside senescent cells. Normal (healthy) cells keep FOXO4 and p53 largely separated. Senescent cells, however, show nuclear FOXO4 that sequesters p53 away from mitochondria, preventing the cell from triggering its own apoptosis program. FOXO4-DRI competes with endogenous FOXO4 for p53 binding, releasing p53 to activate apoptosis specifically in these cells.
In the Baar et al. 2017 study, p21-positive senescent cells showed dose-dependent apoptosis in culture. The retro-inverso construction (all D-amino acids in reversed sequence) was specifically chosen to survive the protease-rich environment long enough to reach intracellular targets after endocytosis. This same feature means the peptide is not simply a passive binder; its intracellular destination matters, and the dose required to achieve intracellular concentrations sufficient to displace an established protein-protein interaction is likely higher than surface-receptor peptides. That is part of why the mouse study dose of 5 mg/kg is so high relative to other research peptides.
What the mechanism does NOT prove: disrupting FOXO4-p53 binding in culture does not confirm that subcutaneous injection in a human delivers meaningful intracellular concentrations at the tissue sites where senescent cells accumulate. No pharmacokinetic study in any mammal has measured tissue distribution or intracellular concentration after injection.
Evidence Ledger: What the Data Actually Supports
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| FOXO4-DRI selectively induces apoptosis in senescent cells in culture | In vitro (Baar et al. 2017) | Positive | Moderate |
| 5 mg/kg IP 3x/week clears senescent cells in fast-aging mice | Animal RCT-equivalent (Baar et al. 2017, n=small cohort of XFE progeroid mice) | Positive | Moderate (animal only) |
| FOXO4-DRI improves physical fitness and organ markers in treated mice | Animal study (Baar et al. 2017) | Positive | Low (no human translation confirmed) |
| Any specific human dose is effective or safe | No clinical trial data | Unknown | Very Low |
| 1 to 2 mg/kg subcutaneous dosing achieves relevant plasma concentrations | No pharmacokinetic study | Unknown | Very Low |
| D-amino acid backbone increases stability vs. all-L peptides | Biochemistry/mechanism (general peptide literature) | Positive (stability) | High (general principle) |
| Oral bioavailability is meaningful | No evidence; mechanistically implausible | Negative | High confidence it does NOT work orally |
FOXO4-DRI Dosage Chart by Body Weight
| Body Weight (kg) | Mouse-Study Equivalent (5 mg/kg) | Low Human-Extrapolated Dose (1 mg/kg) | Mid Human-Extrapolated Dose (2 mg/kg) |
|---|---|---|---|
| 60 kg | 300 mg | 60 mg | 120 mg |
| 70 kg | 350 mg | 70 mg | 140 mg |
| 80 kg | 400 mg | 80 mg | 160 mg |
| 90 kg | 450 mg | 90 mg | 180 mg |
| 100 kg | 500 mg | 100 mg | 200 mg |
The mouse-equivalent column illustrates why direct allometric scaling is impractical: 300 to 500 mg of a synthetic peptide per injection has never been tested in humans and would be extraordinarily expensive from any source. Researchers who extrapolate downward to 1 to 2 mg/kg are making a pragmatic assumption, not a pharmacologically validated one.
Injection Frequency and Protocol Structures
The Baar et al. 2017 mouse study used three injections per week. Self-experimentation communities report a range of frequencies, from three times per week to once per week, and some users describe pulse protocols (a defined number of weeks on, followed by an extended break) modeled loosely on the logic that senolytic clearance may not need to be continuous once a senescent cell burden is reduced. None of these human protocol structures have been tested in any controlled study.
| Protocol Type | Frequency | Source Basis | Evidence Level |
|---|---|---|---|
| Mouse study protocol | 3x per week, ongoing | Baar et al. 2017 | Animal study only |
| High-frequency human extrapolation | 3x per week | Direct copy of mouse frequency | No human data |
| Low-frequency human extrapolation | 1x per week | Self-experimentation communities | Anecdotal only |
| Pulse protocol | Short course (e.g., 3 weeks) then long break | Theoretical; no supporting study | Speculation |
Reconstitution and Operational Label Literacy
FOXO4-DRI is sold as lyophilized (freeze-dried) powder, typically in vials of 5 mg or 10 mg. Reconstitution steps:
- Allow the vial to reach room temperature before opening to prevent condensation from contacting the powder.
- Draw the desired volume of bacteriostatic water (preferred for multi-use vials) or sterile water for injection (single use) into a syringe.
- Inject the water slowly along the inner glass wall of the vial, not directly onto the powder cake. This minimizes mechanical disruption of peptide structure.
- Swirl gently for 30 to 60 seconds. Do not shake, which introduces air bubbles and can cause peptide aggregation at the air-liquid interface.
- Inspect for clarity: the solution should be clear and colorless.
Concentration math example: Adding 2 mL of bacteriostatic water to a 10 mg vial yields a 5 mg/mL solution. To deliver 80 mg, you would draw 16 mL, which is not a practical subcutaneous injection volume. This arithmetic alone illustrates that 1 to 2 mg/kg human doses require either high-concentration reconstitution or multiple injection sites.
Reading a COA: Look for HPLC purity listed as a percentage (98% or above is a reasonable minimum for research use), and mass spectrometry data confirming the molecular weight matches FOXO4-DRI (calculated molecular weight is approximately 2,305 Da, though verify against the supplier's stated sequence). Absence of endotoxin testing (LAL assay) on a COA is a red flag for injectable research peptides.
What Most Dosage Pages Get Wrong
Most FOXO4-DRI dosage pages present a single figure (often 1 to 2 mg/kg) as if it were a clinical dose derived from human trials. It is not. It is a downward scaling from a mouse study, and the gap between mouse and human pharmacokinetics for a peptide of this type is large and unstudied.
A second common error: presenting the Baar et al. results in wild-type old mice (where benefits were modest) and the XFE progeroid mice (where benefits were dramatic) as equivalent. The progeroid mice have an accelerated senescence phenotype that does not map cleanly onto normal human aging. The most dramatic "before and after" images in the study came from animals with a severe DNA repair defect, not from normal aging.
Third: ignoring route of administration differences. The mouse study used intraperitoneal injection, which delivers peptide directly into the abdominal cavity with rapid systemic absorption. Human self-experimenter protocols typically use subcutaneous injection, which has a slower and often lower bioavailability for peptides. Whether subcutaneous delivery achieves equivalent tissue concentrations is unknown.
Storage and Stability: The Chemistry Behind the Rules
Lyophilized FOXO4-DRI should be stored at minus 20 degrees Celsius or colder. After reconstitution, store at 2 to 8 degrees Celsius and use within approximately 4 weeks. The reasons behind these rules:
Why freeze the lyophilized powder? In the dry state, peptide degradation occurs primarily through oxidation (of methionine or cysteine residues, if present) and slow Maillard-type reactions if any residual sugars from lyophilization excipients are present. Low temperature slows both reaction types by reducing molecular mobility. At room temperature, lyophilized peptides still degrade over months.
Why limit freeze-thaw cycles after reconstitution? Each freeze-thaw cycle stresses the peptide at the ice-crystal interface, promoting aggregation and beta-sheet formation. Aggregated peptide loses biological activity and may carry an increased immunogenicity risk. Aliquotting before freezing reconstituted peptide into single-use portions eliminates this problem.
Why does the D-amino acid backbone help? Endogenous proteases (trypsin, chymotrypsin, elastase) evolved to cleave L-amino acid peptide bonds. The retro-inverso construction of FOXO4-DRI, using all D-amino acids in reversed sequence, presents a non-natural substrate. Studies on retro-inverso peptides broadly show substantially longer plasma half-lives compared to their all-L equivalents, though exact kinetics for FOXO4-DRI have not been published. This is the genuine chemical justification for the retro-inverso design, not marketing language.
Honest Head-to-Head: FOXO4-DRI vs. Other Senolytics
| Compound | Mechanism | Human Trial Data | Known Human Risks | Route | Where It Loses |
|---|---|---|---|---|---|
| FOXO4-DRI | Disrupts FOXO4-p53 interaction, triggers senescent cell apoptosis | None | Unknown | Injectable only | No human data whatsoever; cost at effective doses is very high |
| Navitoclax (ABT-263) | BCL-2/BCL-XL inhibitor; blocks anti-apoptotic proteins | Multiple oncology trials; senolytics trials ongoing (e.g., at Mayo Clinic) | Dose-limiting thrombocytopenia in humans (platelet BCL-XL dependence) | Oral | Thrombocytopenia is a serious and well-documented human risk |
| Dasatinib plus Quercetin (D+Q) | Tyrosine kinase inhibition (dasatinib) plus flavonoid (quercetin) | Small pilot human trials published (Kirkland group, Mayo Clinic) | Dasatinib: GI toxicity, pleural effusion risk at chronic doses | Oral | Dasatinib is an FDA-approved chemotherapy drug with a significant adverse effect profile |
| Fisetin | Flavonoid; reduces senescent cell burden (animal data) | Small human trial data, limited | Generally regarded as low risk at studied doses | Oral | Weakest preclinical efficacy signal of the group; bioavailability is poor |
FOXO4-DRI's theoretical advantage is selectivity for the FOXO4-p53 axis, which could spare non-senescent cells better than BCL-2 inhibitors. However, this selectivity has only been demonstrated in culture and in progeroid mice, and the lack of any human data means it cannot be ranked above approaches with actual human trial evidence.
Failure Modes and Sourcing Reality
The research peptide market is unregulated in most jurisdictions. Independent testing of peptides purchased from online suppliers has repeatedly found issues including incorrect concentration, wrong sequence, incomplete deprotection of synthesis intermediates, and bacterial endotoxin contamination. For a compound that requires injection and where the intended dose is in the tens to hundreds of milligrams range, these are not trivial concerns.
Minimum sourcing standards for FOXO4-DRI:
- HPLC purity certificate at 98% or above
- Mass spectrometry confirmation that the molecular weight matches the expected sequence
- Endotoxin (LAL) testing certificate, with results below the standard threshold for injectable use (typically less than 5 EU/mg)
- Sequence confirmation or amino acid analysis is a higher bar that few suppliers meet
Signs of a degraded or contaminated solution: cloudiness, yellow or brown discoloration, visible particulates, or an unexpected smell after reconstitution. Any of these are discard signals. A properly reconstituted solution should be clear and colorless. If a vial reconstitutes with visible aggregates that do not dissolve with gentle swirling, do not inject it.
FAQ
What is the standard FOXO4-DRI dosage used in research?
The original Baar et al. 2017 mouse study used 5 mg/kg injected intraperitoneally three times per week. There is no validated human clinical trial dose. Human protocols circulating in self-experimentation communities typically range from 1 mg/kg to 2 mg/kg subcutaneously, but these are extrapolations without human safety or efficacy data.
How do you calculate a FOXO4-DRI dose by body weight?
Multiply your body weight in kilograms by the target mg/kg figure. An 80 kg person at 1 mg/kg would require 80 mg per injection. At 5 mg/kg (the mouse study dose), that rises to 400 mg, an amount that is cost-prohibitive and untested in humans.
How often should FOXO4-DRI be injected?
The mouse study administered doses three times per week. Self-experimentation communities report protocols ranging from three times per week to once per week. No human study has established an optimal injection frequency.
Can FOXO4-DRI be taken orally?
No. FOXO4-DRI is a peptide. Oral administration would result in rapid proteolytic degradation in the gastrointestinal tract before systemic absorption. All published research used injectable routes.
How do you reconstitute FOXO4-DRI powder?
Lyophilized FOXO4-DRI is typically reconstituted with bacteriostatic water. Add the solvent slowly along the vial wall rather than directly onto the powder, then swirl gently. Do not shake. Calculate the volume needed to achieve your target concentration (e.g., adding 2 mL to 10 mg yields 5 mg/mL).
What does a degraded FOXO4-DRI solution look like?
Degraded or contaminated solution may appear cloudy, discolored (yellow or brown), or contain visible particulates. A properly reconstituted solution should be clear and colorless. Any cloudiness after reconstitution is a discard signal.
Is there human clinical trial data for FOXO4-DRI?
As of mid-2026, no published human clinical trials have evaluated FOXO4-DRI safety or efficacy. All mechanistic and efficacy data come from mouse studies and in vitro work. Human use remains experimental and without regulatory approval.
What are the risks of using FOXO4-DRI?
Theoretical risks include off-target apoptosis in non-senescent cells, immune reactions, and unknown long-term effects. Practical risks include peptide purity issues from unregulated suppliers, injection site reactions, and contamination from improperly reconstituted product. No human safety profile has been established.
How should reconstituted FOXO4-DRI be stored?
Lyophilized powder should be stored at minus 20 degrees Celsius or colder. After reconstitution, store at 2 to 8 degrees Celsius and use within 4 weeks. Avoid repeated freeze-thaw cycles, which accelerate peptide bond degradation.
How does FOXO4-DRI compare to other senolytics like navitoclax?
Navitoclax (ABT-263) has human clinical trial data in oncology and is being studied in senolytics trials. FOXO4-DRI has no human trial data. Navitoclax causes dose-limiting thrombocytopenia in humans. FOXO4-DRI's human side-effect profile is unknown. Neither is approved for anti-aging use.
What is the half-life of FOXO4-DRI?
No published pharmacokinetic study has measured the plasma half-life of FOXO4-DRI in humans or primates. The D-amino acid backbone is expected to slow protease-mediated degradation compared to all-L peptides, but exact figures have not been published in peer-reviewed literature.
Does FOXO4-DRI have WADA or regulatory status to be aware of?
FOXO4-DRI is not currently listed by name on the WADA prohibited list, but it may fall under catch-all categories for peptides with growth-related or apoptosis-modifying activity. It has no FDA approval, no EMA approval, and is regulated as a research chemical in most jurisdictions.
Sources
- Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132-147.e16. PMID: 28340339.
- Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518-536. PMID: 32686219.
- Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644-658. PMID: 25754370.
- van Deursen JM. The role of senescent cells in ageing. Nature. 2014;509(7501):439-446. PMID: 24848057.
- Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554-563. PMID: 30616998.
- Muñoz-Espín D, Serrano M. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol. 2014;15(7):482-496. PMID: 24954210.
- Checler F, Alves da Costa C. p53 in neurodegenerative diseases and brain cancers. Pharmacol Ther. 2014;142(1):99-113. PMID: 24316434.
- Verdine GL, Hilinski GJ. Stapled peptides for intracellular drug targets. Methods Enzymol. 2012;503:3-33. PMID: 22230563. (General context on intracellular peptide delivery challenges.)
- Lau YH, de Andrade P, Wu Y, Spring DR. Peptide stapling techniques based on different macrocyclisation chemistries. Chem Soc Rev. 2015;44(1):91-102. PMID: 25199043.
Footer Disclaimers
Platform: FormBlends provides educational and informational content only. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before using any research compound.
Research Compound: FOXO4-DRI is a research peptide. It has not been approved by the FDA, EMA, or any equivalent regulatory authority for human therapeutic use. It is not a licensed drug or dietary supplement.
Results: Individual outcomes, if any, from research compounds are highly variable and not predictable. No claims are made that FOXO4-DRI produces any specific result in humans.
Trademark: All product names, trademarks, and registered trademarks mentioned are the property of their respective owners. Their use on this page is for identification and educational purposes only and does not imply endorsement.